Articles on this page are updated by ProfileData Research on an hourly basis. To see the summary of the SENS notice, please click on the headline. To read the original SENS message, please click on the link in the summary.



Date Headline/Title
11 November 2026Regulatory Approvals for Aspen’s Generic Injectable Semaglutide in Brazil and South Africa
10 November 2026Notification in terms of Section 122 (3)(b) of the Companies Act and Section 6.54 of the JSE Listings Requirements
10 November 2026Dealing in Securities by a Director, Prescribed Officer and the Company Secretary of Aspen and the Company Secretary of a Major Subsidiary of Aspen
09 November 2026Vesting of Share Awards of Directors, Prescribed Officers and the Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
09 November 2026Grant and Acceptance of Share Awards by Directors, Prescribed Officers and The Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
09 November 2026Dealing in Securities by a Prescribed Officer
09 November 2026Vesting of Share Awards of Directors, Prescribed Officers and the Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
09 November 2026Grant and Acceptance of Share Awards by Directors, Prescribed Officers and The Company Secretary of Aspen and a Director and the Company Secretary of a Major Subsidiary of Aspen
09 November 2026Dealing in Securities by a Prescribed Officer
05 November 2026General Repurchase of Ordinary Shares: Subsequent 3% Repurchase
05 November 2026Update on the Divestment of a Women’s Health Product in Europe to Ennogen
05 November 2026General Repurchase of Ordinary Shares: Subsequent 3% Repurchase
05 November 2026Update on the Divestment of a Women’s Health Product in Europe to Ennogen
02 November 2026Divestment of a Women’s Health Product in Europe to Ennogen
23 October 2026Availability of Integrated Reporting Suite, B-BBEE Verification Certificate and Further Notice of Annual General Meeting
02 October 2026No Change Statement, Availability of Audited Annual Financial Statements and Notice of Annual General Meeting
02 September 2026Aspen final results June 2026
02 September 2026General repurchase of ordinary shares
21 August 2026Business update and trading statement for the year ended 30 June 2026
03 August 2026Notice regarding the Release of Aspen’s Financial Results for the year ending 30 June 2026, and Results Presentation
20 July 2026Health Canada approves Aspen-Semaglutide
09 July 2026Proposed Succession and Board Composition Update
02 July 2026Notification in terms of Section 122 (3)(b) of the Companies Act and Section 6.54 of the JSE Listings Requirements
25 June 2026Dealing in Securities by a Prescribed Officer
22 June 2026Change in Chairmanship of the Audit and Risk Committee
29 May 2026Completion of the divestment of Aspen APAC
21 May 2026Dealing in Securities by a Director and Prescribed Officer
05 May 2026Dealing in Securities by a Director and Prescribed Officer
05 May 2026Commercial Release of Locally Manufactured Human Insulin
30 April 2026Resignation of Executive Director
21 April 2026Results of the general meeting
19 March 2026Distribution of circular to shareholders and notice of general meeting
03 March 2026Aspen interim results December 2025
11 February 2026Business Update and Trading Statement for the six months ended 31 December 2025
06 February 2026Notice regarding the release of Financial Results for the six months ended 31 December 2025 and Results Presentation
13 January 2026Proposed divestment of Aspen APAC (excluding China) – live webcast details
Powered by ProfileData